Prevention Goes Mainstream
nazih@lol
−2.7%
since Sep 30
The idea
I believe GLP-1 drugs are shifting medicine from treatment to prevention, with tens of millions on these therapies for years to come. The obvious Lilly and Novo trade is priced in, so I anchor there but put more weight into next-generation pipeline plays like oral pills and muscle-preserving combos, plus the supplier layer making pens, glass, and fill-finish capacity that wins regardless of which drug leads. I size the speculative biotech names small, keep a cash reserve to add on dips, and treat this as a multi-year structural shift rather than a quick trade.
What it owns
- When tens of millions of people take weekly injectables, the pen makers, cartridge makers, and manufacturers-for-hire win regardless of whose drug leads. · Thermo Fisher ScientificIt gets paid to make and fill these drugs for whoever wins, and manufacturing capacity stays a bottleneck the drugmakers outsource., West Pharmaceutical ServicesIt makes the components inside injector pens, so recurring orders for tens of millions of people on weekly shots flow regardless of which drug leads., Hims & Hers HealthIt's the access layer, building the channel to get these drugs to millions of ordinary people cheaply as prevention goes mainstream., Becton DickinsonIt supplies pen needles and injection devices at the scale mass prevention requires, winning on volume as injected GLP-1s keep growing., Stevanato GroupIt makes the glass cartridges every injectable GLP-1 needs, and that glass is one of the tightest bottlenecks in scaling these drugs.34%
- The bigger upside is in drugs after this generation: pills, monthly shots, and combinations that preserve muscle. · AmgenIts MariTide bets that monthly dosing instead of weekly shots wins over the tens of millions who'd stay on these drugs for years., Viking TherapeuticsIts dual-agonist drug has posted strong weight-loss data and is exactly the kind of smaller biotech the giants may acquire., AstraZenecaIt's working on oral GLP-1 candidates, the pill format that could make prevention drugs cheap enough to go truly mass market., Regeneron PharmaceuticalsIt's developing combinations that preserve muscle while stripping weight, which matters if people are on these drugs for years., PfizerThe stock prices in almost nothing for GLP-1s after earlier setbacks, so any successful oral candidate or acquisition is nearly free upside., AltimmuneIts pemvidutide is built to spare lean mass while cutting weight, aimed at the biggest complaint about long-term GLP-1 use., Structure TherapeuticsIt's a pure play on the oral GLP-1 pill, the format that could take these drugs from injections for some to daily prevention for tens of millions., Scholar RockIts muscle-preserving drug is designed to be taken alongside GLP-1s, so it wins if long-term prevention users need to protect muscle regardless of whose weight-loss drug they take.33%
- These two companies dominate today's prevention-drug market and fund the next decade of it. · Eli LillyIt anchors this take with tirzepatide and an oral pill pipeline that could capture the biggest share if GLP-1 drugs move medicine from treatment to prevention., Novo NordiskIt's the other anchor, with semaglutide already proving the prevention case in heart and kidney outcomes trials.24%
- Cash10%